Destined for IPO? Fate looks to raise $69m
This article was originally published in Scrip
Executive Summary
Fate Therapeutics is looking to tempt investors with a $69 million initial public offering to finance Phase II clinical trials for a therapy that is designed to improve hematopoietic stem cell (HSC) transplant efficacy and for additional preclinical programs.